Meryl Zausner

Member of Board of Directors at Seres Therapeutics and Goldfinch Bio

Meryl Zausner is a highly accomplished C-suite executive with over 35 years of management experience in the pharmaceutical and consumer products industries.

During her 29-year successful career at Novartis, Meryl played a key role in establishing the Novartis Oncology Business Unit and spearheading the launch of the first Novartis shared services organization.

She is renowned for her talent development initiatives and was honored with the prestigious Woman of the Year Award by the Healthcare Businesswomen's Association.

Meryl is a sought-after advisor in areas such as strategy, finance, and leadership and has served on public and nonprofit boards.

Her academic background includes studying Executive Coaching, Finance, and General Management at Harvard Business School Corporate Executive Programs, as well as earning a B.S. in Accounting and Economics from the University at Albany, SUNY.

Meryl currently serves as the Audit Committee Chair and a member of the Governance Committee at Goldfinch Bio, and has previously held board positions at organizations like Seres Therapeutics and Neon Therapeutics.

Her extensive career at Novartis involved roles like EVP CFO, Country CFO, Executive Coach, and EVP & CFO of various divisions within the company, showcasing her versatile skill set.

Prior to Novartis, Meryl held finance and leadership positions at companies like Colgate-Palmolive and David Berdon and Company, further enriching her experiences and expertise in the industry.